Project Details
| Status | Active |
|---|---|
| Effective start/end date | 1/18/24 → 1/18/27 |
Funding
- Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1403-0019)
Prot #1403-0019: Brightline-4: A Phase III Open-Label, Single-Arm, Multi-Center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-Naïve or Pre-Treated Advanced Dedifferentiated Liposarcoma
Project: Research project